Breast Cancer

Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer

August 6th 2022, 8:24pm


The approval came exactly 2 months after results from the landmark DESTINY-Breast04 trial showed that the antibody drug conjugate reduced the risk of disease progression or death by 50% compared with chemotherapy for HER2-low patients with both hormone receptor (HR)–positive and HR-negative disease.

Dr Debra Patt on Capturing the HER2-Low Population

July 24th 2022, 2:16pm


Understanding that patients who are HER2-low are different from patients who are HER2-positive and -negative means having the right way to evaluate and identify these patients, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.

Dr Hope S. Rugo Discusses Clinical Trial Minority Recruitment, PALOMA-2 Findings

June 16th 2022, 10:26am


Hope S. Rugo, MD, FASCO, is professor of medicine and the director of the Breast Oncology and Clinical Trials Education program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. She discusses her experience with palbociclib and letrozole in advanced breast cancer.

Dr Debra Patt Addresses the Importance of Cancer Screening Awareness, Strong Health Care Infrastructure

May 11th 2022, 9:17pm


Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how community oncology practices have heightened their outreach efforts to entice patients back in for cancer screenings and the importance of thinking outside the box to overcome staffing shortages in the oncology space.

Ribociclib Data Show Reduced Mortality Risk in HR+/HER2- Advanced Breast Cancer

May 9th 2022, 2:02pm


Officials from Novartis emphasized that the ribociclib-fulvestrant combination is the only one in the CDK4/6 inhibitor class to demonstrate an overall survival benefit when used in a first-line setting among postmenopausal women.

FDA Approves Enhertu for Use in Metastatic Breast Cancer

May 5th 2022, 4:57pm


This approval of trastuzumab deruxtecan (Enhertu) follows the March release of data from the DESTINY-Breast03 trial on the anti-HER2 monoclonal antibody, also a HER2-directed antibody-drug conjugate, which indicated superior outcomes vs trastuzumab emtansine.

Dr Hatem Soliman Explains Short-, Long-term Treatment Priorities for Metastatic Disease

May 3rd 2022, 6:45pm


The intent of metastatic disease treatment is palliative, not curative, so we try to prolong life and provide quality of life as much as we can, said Hatem Soliman, MD, medical director of the Clinical Trials Office, Moffitt Cancer Center.

Contributor: Helping Women of Color Achieve a Healthier Future

April 27th 2022, 6:43pm


To achieve health equity, experts from CVS Health discuss why we must invest in programs that improve access to health care for historically marginalized communities, address social determinants, boost health education, increase representation in all levels of health care delivery, widen access to clinical trial research, and more.

Dr Hatem Soliman Addresses the Economic Burden of Metastatic Breast Cancer Treatment

April 25th 2022, 2:46pm


The financial toxicity of newer metastatic breast cancer (MBC) treatments is a significant concern and requires stakeholders to work together to find the best value- and evidence-based treatments for patients, said Hatem Soliman, MD, medical director, Clinical Trials Office, Moffitt Cancer Center.

Dr Debra Patt: The True Impact of the Pandemic on Cancer Screenings, Diagnoses Is Not Yet Known

April 23rd 2022, 12:41pm


Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses how the pandemic may have influenced cancer screening and diagnosis rates.